Breaking News, Collaborations & Alliances

Gilead, MicroDose Enter RSV Pact

Gilead Sciences and MicroDose Therapeutx have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of MDT-637, MicroDose’s inhalable small molecule antiviral fusion inhibitor for the treat

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead Sciences and MicroDose Therapeutx have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of MDT-637, MicroDose’s inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV). MicroDose will receive an upfront payment and research funding to support development of MDT-637 through Phase IIa trials, after which Gilead can assume full development responsibility. MicroDose is also ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters